Analyst Ratings For Fate Therapeutics (NASDAQ:FATE)
Today, HC Wainwright reiterated its Hold rating on Fate Therapeutics (NASDAQ:FATE) with a price target of $12.00.
Some recent analyst ratings include
- 3/20/2018-HC Wainwright Reiterated Rating of Hold.
- 3/6/2018-Wedbush Reiterated Rating of Outperform .
- 3/6/2018-Wells Fargo Reiterated Rating of Outperform.
- 3/6/2018-Piper Jaffray Companies Reiterated Rating of Overweight .
- 12/12/2017-Raymond James Financial Reiterated Rating of Buy.
- 9/8/2017-Leerink Swann Reiterated Rating of Outperform .
Recent Insider Trading Activity For Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics (NASDAQ:FATE) has insider ownership of 10.88% and institutional ownership of 66.43%.
- On 10/16/2017 Cindy Tahl, General Counsel, sold 8,091 with an average share price of $3.85 per share and the total transaction amounting to $31,150.35.
- On 10/16/2017 Daniel D Shoemaker, Insider, sold 13,225 with an average share price of $3.87 per share and the total transaction amounting to $51,180.75.
- On 11/23/2016 Chris Storgard, Insider, bought 37,593 with an average share price of $2.66 per share and the total transaction amounting to $99,997.38.
- On 11/23/2016 William H Rastetter, Director, bought 375,939 with an average share price of $2.66 per share and the total transaction amounting to $999,997.74.
- On 6/12/2014 Peter D Flynn, Insider, sold 6,488 with an average share price of $7.00 per share and the total transaction amounting to $45,416.00.
- On 6/10/2014 Peter D Flynn, Insider, sold 3,305 with an average share price of $7.00 per share and the total transaction amounting to $23,135.00.
- On 5/1/2014 Peter D Flynn, Insider, sold 9,793 with an average share price of $7.07 per share and the total transaction amounting to $69,236.51.
Recent Trading Activity for Fate Therapeutics (NASDAQ:FATE)
Shares of Fate Therapeutics closed the previous trading session at 11.59 down -0.13 1.11% with 11.770000457763672 shares trading hands.
